7 results
CORRESP
CPHI
China Pharma Holdings, Inc.
8 Sep 23
Correspondence with SEC
12:00am
to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. Since these statements and regulatory actions … substantial costs and unforeseen risks.
CSRC Filing Requirements and Cybersecurity Review in the PRC
As China Pharma is already publicly listed
424B5
pa3n0qrkfli9p
16 Dec 21
Prospectus supplement for primary offering
4:05pm
- Prev
- 1
- Next